ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Autoantibody(ies)"

  • Abstract Number: 0098 • ACR Convergence 2024

    Anti-HSP90α as a Protective Natural Antibody Against Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus

    Marina Barguil Macedo1, Jorge Armando Gonzalez-Chapa1, Anders Bengtsson2, Iva Gunnarsson3, Elisabet Svenungsson4 and Christian Lood1, 1University of Washington, Seattle, WA, 2Lund University, Lund, Sweden, 3Karolinska Institute, Stockholm, Sweden, 4Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Heat shock protein 90 alpha (HSP90α) is an epichaperone present ubiquitously inside the cell, whose dimers function as a foldase that helps the correct…
  • Abstract Number: 0444 • ACR Convergence 2024

    Deep Serologic Profiling Identifies Novel Autoantibodies Associated with Fetal Atrioventricular Block

    Philip Carlucci1, Robert Clancy2, Mala Masson3, Colin Phoon4, Ashley Roman4, Peter Izmirly5, Amit Saxena6, H Michael Belmont4, Christina Penfield4, Young Mi Lee4, Julie Nusbaum7, Andrew Rubenstein4, Ruben Acherman8, Elena Sinkovskaya9, Alfred Abuhamad9, Karla Bermudez-Wagner9, Majd Makhoul10, Gary Satou11, Whitnee Hogan12, Nelangi Pinto13, Anita Moon-Grady14, Lisa Howley15, Mary Donofrio16, Anita Krishnan16, Jaclyn Phillips17, Stephanie Levasseur18, Miwa Geiger19, Erin Paul20, Sonal Owens21, Kristopher Cumbermack22, Jyothi Matta23, Gary Joffe24, Christopher Lindblade25, Carl Weiner26, Caitlin Haxel27, Katherine Kohari28, Joshua Copel28, James Strainic29, Tam Doan30, Shreya Sheth30, Stacy Killen31, Theresa Tacy32, Michelle Kaplinski32, Nicola Fraser4, Kelly Ruggles33, Bettina Cuneo34 and Jill Buyon35, 1New York University School of Medicine, New York, NY, 2Columbia University Medical Center, New York, NY, 3NYU Langone Medical Center- Division of Rheumatology, New York, NY, 4NYU Langone Health, New York, NY, 5New York University Grossman School of Medicine, New York, NY, 6NYU Grossman School of Medicine, New York, NY, 7NYU Langone Hospital - Long Island, Internal Medicine - Rheumatology, Mineola, NY, 8Children's Heart Center, Las Vegas, NV, 9Eastern Virginia Medical School, Norfolk, VA, 10Atrium Health Levine Children's Hospital, Charlotte, NC, 11University of California Los Angeles, Los Angeles, CA, 12University of Utah, Salt Lake City, UT, 13Seattle Children's Hospital, Seattle, WA, 14University of California San Francisco, San Francisco, CA, 15Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, 16Children's National Hospital, Washington, DC, 17George Washington University, Washington, DC, 18Columbia University, New York, NY, 19Mount Sinai School of Medicine, New York, NY, 20Atlantic Health System, Morristown, NJ, 21University of Michigan, Ann Arbor, MI, 22University of Kentucky, Lexington, KY, 23University of Louisville, Louisville, KY, 24Perinatal Associates of New Mexico, Albuquerque, NM, 25Phoenix Children's Hospital, Phoenix, AZ, 26Dignity Health, Phoenix, AZ, 27University of Vermont Children's Hospital, Burlington, VT, 28Yale University, New Haven, CT, 29UH Rainbow Babies, Cleveland, OH, 30Baylor College of Medicine, Houston, TX, 31Vanderbilt University, Nashville, TN, 32Stanford University, Stanford, CA, 33NYU Grossman School of Medicine, Brooklyn, NY, 34University of Arizona College of Medicine, Tucson, AZ, 35New York University Grossman School of Medicine, New York, NY

    Background/Purpose: Maternal anti-SSA/Ro52/60kD autoantibodies are necessary for the development of fetal atrioventricular block (AVB) but titers alone are not sufficient to predict the likelihood of…
  • Abstract Number: 0840 • ACR Convergence 2024

    The Platelet Adenosinergic Axis as a Novel Therapeutic Target for Thrombotic APS

    NaveenKumar Somanathapura K1, Thalia Newman2, Srilakshmi Yalavarthi1, Bruna Mazetto Fonseca1, Kaitlyn Sabb1, Katarina Kmetova3, Emily Chong1, Caroline Ranger1, Cyrus Sarosh4, Jacqueline Madison1, Ajay Tambralli1, Jordan Schaefer1, Michael Holinstat1, Yu Zuo1 and Jason Knight1, 1University of Michigan, Ann arbor, MI, 2University of Michigan, Ann Arbor, MI, 3Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, 4University of Michigan, Temperance, MI

    Background/Purpose: How to most effectively inhibit antiphospholipid antibodies (aPL)-mediated platelet activation remains incompletely understood. CD73 is an ectoenzyme expressed on the platelet surface that generates…
  • Abstract Number: 1490 • ACR Convergence 2024

    Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests

    Vasileios Kyttaris1, Andrew Concoff2, Touba Warsi3, Sepehr Taghavi3, Sudha Kumar3, Stanley Park3, Abigail Patalinghug3, Christine Schleif3, Brittany Partain4, Joseph Ahearn5, Nicole Wilson6, Chau-Ching Liu6, Susan Manzi6 and Tyler O'Malley7, 1BIDMC, Boston, MA, 2Exagen, Inc., Los Angeles, CA, 3Exagen, Carlsbad, CA, 4Exagen, Boston, MA, 5Allegheny Health Network, Wexford, PA, 6Allegheny Health Network, Pittsburgh, PA, 7Exagen, Vista, CA

    Background/Purpose: Conventional SLE diagnostic markers lack sensitivity and are biased towards severe disease, resulting in a subset of clinically ambiguous ANA-positive but specific autoantibody-negative patients.…
  • Abstract Number: 1687 • ACR Convergence 2024

    IgG and IgA anti-LIN28A Outperform Anti-dsDNA and anti-Sm in Distinguishing SLE from Health and Other Autoimmune Diseases

    Ioannis Parodis1, Dionysis Nikolopoulos2, Julius Lindblom3, Denis Lagutkin3, Lorenzo Beretta4, Maria Orietta Borghi5, Janique Peyper6, Guillermo Barturen7, Per-Johan Jakobsson3, Marta Alarcon-Riquelme8, Natalia Sherina3 and Helena Idborg9, and PRECISESADS Clinical Consortium, 1Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, 2Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, 3Karolinska Institutet, Stockholm, Sweden, 4Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, 5Università degli Studi di Milano Statale, Milano, Italy, 6Sengenics Corporation Pte Ltd, Singapore, Singapore, 7Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, 8Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 9Karolinska Institutet, Solna, Sweden

    Background/Purpose: Systemic lupus erythematosus (SLE) is characterised by the production of a multitude of autoantibodies (abs). The diagnosis of SLE is supported by the presence…
  • Abstract Number: 2065 • ACR Convergence 2024

    Proposed Pathways Involved in the Pathogenesis of Juvenile Dermatomyositis (JDM)

    Samantha Coss1, Danlei Zhou1, Rabheh Abdul Aziz2, Katherine Miller3, Shoghik Akoghlanian4, Kyla Driest1, Edward Oberle1, Vidya Sivaraman5, Charles Spencer6, Stacy Ardoin1 and Chack-Yung Yu7, 1Nationwide Children's Hospital, Columbus, OH, 2University at Buffalo, Buffalo, NY, 3Nationwide Children's Hospital, Institute for Genomic Medicine, Columbus, OH, 4Nationwide Children�s Hospital, Columbus, OH, 5Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, 6University of Mississippi Medical Center, Jackson, MS, 7Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, OH

    Background/Purpose: JDM is an autoimmune disease of skin and muscle. We investigated genetic factors, autoantibodies, and clinical features in JDM.Methods: Subjects came from 2 large…
  • Abstract Number: 2471 • ACR Convergence 2024

    Association of Telangiectasias with Autoantibodies and Clinical Manifestations in Systemic Sclerosis

    Namitha Nair1, Thomas Medsger, Jr2, Robert Lafyatis3, Maureen Laffoon4, Leigh Freno4 and Robyn Domsic5, 1University of Pittsburgh Medical Center, Pittsburgh, PA, 2Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Verona, PA, 3University of Pittsburgh, Pittsburgh, PA, 4UPMC, Pittsburgh, PA, 5Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA

    Background/Purpose: Telangiectasias (Tel) are visibly dilated cutaneous post-capillary venules reported to occur in about 75% of patients with systemic sclerosis (SSc), making them a common…
  • Abstract Number: 0099 • ACR Convergence 2023

    Cell-bound Complement Activation Products in Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases

    Doruk Erkan1, JoAnn Vega1, Tyler O'Malley2 and Andrew Concoff3, 1Hospital for Special Surgery, New York, NY, 2Exagen, Vista, CA, 3Exagen, Los Angeles, CA

    Background/Purpose: Based on animal models, complement activation is part of Antiphospholipid Syndrome (APS) pathogenesis. However, studies investigating complement activation in antiphospholipid antibody (aPL)-positive patients are…
  • Abstract Number: 0581 • ACR Convergence 2023

    Performance Characteristics of a Novel, Fully Automated Multiplexed Immunoassay Microarray Prototype for the Serological Detection of Eleven IgG Autoantibodies Commonly Found in Connective Tissue Diseases

    Daphne Bijlsma, Ewa Lukasik, Michael Hausmann, Gerber Gomez, Christine Ginocchio and Emmanuel Moreau, Quotient Suisse SA, Eysins, Switzerland

    Background/Purpose: Detection of autoantibodies is key for the identification and prognosis of patients with connective tissue diseases (CTD); however, some current testing methods are manual,…
  • Abstract Number: 0917 • ACR Convergence 2023

    Role of Immunoglobulin Polygenic Risk in Systemic Lupus Erythematosus

    Victor Gothefors-Holm1, Sarah Reid1, Ahmed Sayadi1, Maija-Leena Eloranta1, Martina Frodlund2, Karoline Lerang3, Andreas Jonsen4, Solbritt Rantapää-Dahlqvist5, Anders Bengtsson4, Anna Rudin6, Oyvind Molberg3, Christopher Sjöwall2, Johanna Sandling1, Lars Rönnblom1 and Dag Leonard1, 1Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 2Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, 3Department of Rheumatology, Oslo University Hospital, Oslo, Norway, 4Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, 5Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, 6Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease partly characterized by production of autoantibodies, causing inflammation and tissue damage. In this study…
  • Abstract Number: 1448 • ACR Convergence 2023

    Association of Disease Activity and Anti-Double Stranded DNA Antibodies Titers with Echocardiographic Parameters in Systemic Lupus Erythematosus Patients

    Natalia Guajardo-Jauregui1, Iris Colunga2, José Ramón Azpiri-López2, Dionicio A. Galarza-Delgado2, Jesus Alberto Cardenas-De la Garza3 and Rosa Arvizu-Rivera4, 1Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, 2Hospital Universitario UANL, Monterrey, Mexico, 3Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, 4Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that involves the deposition of immunocomplexes on vital organs, including the heart. Cardiovascular disease is…
  • Abstract Number: 1809 • ACR Convergence 2023

    Clinical Outcome and Antibody Responses Following the Surge of SARS-CoV-2 Omicron Infection Among Patients with Systemic Autoimmune Diseases

    Zhu Chen1, nan xiang1, Qian Wang1, Yuwei Li1, Huizhi Jin1, Guosheng Wang1, Xiaomei Li2, Tengchuan Jin1 and Wei Bao1, 1University of Science and Technology of China, Hefei, China, 2University of Science and Technology of China, Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Hefei, China

    Background/Purpose: The surge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron infections has affected most Chinese residents at the end of 2022, including…
  • Abstract Number: 2405 • ACR Convergence 2023

    Role of Mitochondria in Activation of Platelets in Giant Cell Arteritis

    Despoina Michailidou1, Peter Grayson2, Payton Hermanson1, Jorge Armando Gonzalez-Chapa1, David Cuthbertson3, Nader A. Khalidi4, Curry Koening5, Carol Langford6, Carol McAlear7, Larry Moreland8, Christian Pagnoux9, Philip Seo10, Antoine G Sreih11, Kenneth Warrington12, Paul Monach13, Peter Merkel7 and Christian Lood1, 1University of Washington, Seattle, WA, 2National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, 3University of South Florida, Tampa, FL, 4McMaster University, Hamilton, ON, Canada, 5University of Texas Dell Medical School, Austin, TX, 6Cleveland Clinic, Cleveland, OH, 7University of Pennsylvania, Philadelphia, PA, 8University of Colorado, Denver, CO, 9Mount Sinai Hospital, Toronto, ON, Canada, 10Johns Hopkins University, Baltimore, MD, 11Bristol Myers Squibb, Princeton Pike, NJ, 12Mayo Clinic, Rochester, MN, 13VA Boston Healthcare System, Boston, MA

    Background/Purpose: We recently found extracellular mitochondrial-derived N-formyl methionine in patients with giant cell arteritis (GCA. Extracellular mitochondria can be extruded by several mechanisms, including platelet…
  • Abstract Number: 0101 • ACR Convergence 2023

    Non-Criteria Antiphospholipid Antibodies and Calprotectin as Potential Biomarkers in Pediatric Antiphospholipid Syndrome

    Elizabeth Sloan1, Katarina Kmetova2, NaveenKumar K. Somanathapura2, Lyndsay Kluge2, Emily Chong2, Claire Hoy2, Srilakshmi Yalavarthi2, Jacqueline Madison2, Cyrus Sarosh2, Lynnette Walters3, Jeanine Baisch4, Jessica Turnier2, Virginia Pascual4, Tracey Wright1, Jason Knight2, Ayesha Zia1 and Yu Zuo2, 1UT Southwestern, Dallas, TX, 2University of Michigan, Ann Arbor, MI, 3Scottish Rite Hospital for Children, Dallas, TX, 4Weill Cornell Medicine, New York, NY

    Background/Purpose: While classification criteria for pediatric APS are not yet available, recent research suggests pediatric APS patients are unique, and many present with extra-criteria manifestations…
  • Abstract Number: 0602 • ACR Convergence 2023

    Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101) Reveals Non-Redundant Roles of T Cell Co-Stimulation Pathways in Systemic Lupus Erythematosus

    Elizabeth Repash, Tiffany Blair, Amanda Enstrom, Lawrence Evans, Susan Debrot, Katherine Lewis, Armand Bankhead, Stanford Peng and Stacey Dillon, Alpine Immune Sciences, Inc., Seattle, WA

    Background/Purpose: CD28 and inducible T cell costimulator (ICOS) play nonredundant roles in T cell activation and inhibiting these pathways can ameliorate an (auto)immune response. Systemic…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology